New mitochondrial microprotein linked to type 2 diabetes discovered

A new study from the University of Southern California has identified a previously unknown microprotein encoded within the human mitochondrial genome that may be involved in certain forms of type 2 diabetes. The discovery suggests that this small peptide could help explain why some patients develop the disease despite having no obvious genetic predisposition in the nuclear genome.

The researchers found that the microprotein is produced by a short open reading frame that had been overlooked in earlier genomic analyses. Preliminary experiments indicate that it may influence insulin signaling pathways or glucose uptake in cells, offering a potential link between mitochondrial function and metabolic regulation. Because the peptide is encoded in the mitochondrial DNA, its expression could vary between individuals, providing a new avenue for precision medicine approaches that target specific metabolic defects.

If further studies confirm the microprotein’s role in diabetes, it could lead to the development of diagnostics that identify patients whose disease is driven by mitochondrial dysfunction. Moreover, therapies designed to modulate the activity or expression of this peptide might offer a tailored treatment strategy for a subset of type 2 diabetes patients, moving the field toward more individualized care.